[바이오타임즈] Recently, the Ministry of Food and Drug Safety (hereinafter Ministry of Food and Drug Safety) has stepped forward to support the development of Antibody-Drug Conjugate (ADC), which is emerging as an essential platform for developing next-generation anticancer drugs.
The Ministry of Food and Drug Safety announced on the 21st that it would publish and distribute the ‘Clinical Pharmacological Consideration Guideline for Antibody-Drug Complexes’, which guides considerations for early clinical trials of ADC. This is part of Regulatory Innovation 2.0 (Task No. 45), which is being pursued to expand treatment opportunities for patients.
Detailed information on the ‘Clinical Pharmacological Considerations Guideline for Antibody-Drug Complexes’ can be found on the Ministry of Food and Drug Safety website → Acts/Resources → Data Room → Guide/Guidelines.
[바이오타임즈=신서경 기자] news@biotimes.co.kr
2023-07-21 20:10:04
#카드뉴스 #developing #antibodydrug #complex #ADC #refer
